In a perfect world, BPC-157 would be vetted in well-done human studies, then widely prescribed by licensed professionals and easily available at compounding pharmacies
"If someone injects it under their skin, what are they getting?" During the COVID-19 pandemic, the FDA issued over a half-dozen warning letters to businesses promoting peptides with "immune-boosting powers." Then in 2023, the agency added nearly 20 peptides to a list of substances that should not be compounded due to safety risks
Intracranial, Portal, and Caval Hypertension
They may contain high-risk ingredients, such as prescription or controlled drugs, and additives or contaminants that may or may not be listed on the label
TB-500 (Thymosin Beta-4) TB-500 is studied for its potential ability to support tissue regeneration and recovery